4^th World Congress on Human Genetics and Genetic Diseases April 19-20, 2018 Dubai, UAE

Currently working at The Chinese University of Hong Kong. And done Ph. D. Chinese Academy of Sciences M. Sc. Northeast Agricultural University B. Sc. Northeast Agricultural University

RF, Probing the molecular function of a bHLH protein in A.annua glandular trichome morphogenesis. An Integrated Functional Genomics Approach towards the Understanding of Artemisinin Metabolism.

John D. Loike, PhD serves as Director for Special Programs for the Center for Bioethics and is the Co-Director for Graduate Studies in the Department of Physiology and Cellular Biophysics at Columbia University College of Physicians and Surgeons. He is also an Advisory Board member of the Columbia University Center for the Study of Science and Religion, creator and faculty editor of the Columbia University Journal of Bioethics, and course instructor for Crossroads in Bioethics, a course for undergraduates offered each spring at Columbia College. He has co-organized several national and international conferences on genetics and Bioethics, and he is the founding co-director of BIOCEP (BIOethical Cross-cultural Education Program), a two-week intensive summer internship program designed to promote educational and cultural exchange in medical ethics (medical tourism, emerging infections, stem cell research, reproductive medicine, etc.) with students from Mahidol University in Bangkok, Thailand.

Dr. Loike’s areas of interest in bioethics include stem cells, cloning, neuroethics, bioterrorism, and the interface of science and religion.

Dr. Michael Nova is the Chief Innovation Officer and founding team member of Pathway Genomics. He is the inventor of all wellness genetic tests, and also the Pathway-IBM/Watson mobile application: OME. His scientific career began at the Salk Institute with Nobel Laureate Roger Guillemin, researching the genetics of growth factors. Michael was the founder/CEO of wireless drug discovery company Discovery Partners Inc. (Nasdaq: DPII; $150M IPO). Dr. Nova is an IBM and Metagenics Advisory Board Member; the 2005 World Economic Forum (WEF) Technology Pioneer Award Winner; and the physician of record on the first person to have their entire genome sequenced by Illumina (2009). He has 35 issued patents, and likes to surf in Indonesia.

Type 2 diabetes (T2D) and obesity are complex disorders that constitute major public health problems. The evidence for familial aggregation of both T2D and obesity is substantial. To date, more than 150 genetic loci are associated with the development of monogenic, syndromic, or multifactorial forms of T2D or obesity; many within lipid and carbohydrate metabolism pathways. SNPs located in or near FTO, MC4R, MC3R, POMC, LEP, LEPR, PLIN1, APOA5, LIPC, FABP2, INSIG2, IRS1, GIPR, ADBR2, ADRB3, UCP1, RETN, ADIPOQ, IL6, PPARG, TCF7L2, and CLOCK, among others, are implicated in both diabetes and obesity gene networks, pleomorphic with nutritional and metabolic traits. A personalized nutritional approach, based not only on phenotypic traits but also on genetic make-up, may help to control body weight and obesity. Recent advances in nutrigenetics, bioinformatics and genome-wide association metabolomics studies are set to unleash a revolution in personalized nutrition. In this symposium, we discuss the evidence concerning the genetic contribution to individual risk of T2D and obesity, and explore the potential role of nutritional and environmental mechanisms.

Dr. Timothy J. Miller, also known as Tim, Ph.D, has been Chief Executive Officer and President of Abeona Therapeutics Inc. formerly known as PlasmaTech Biopharmaceuticals, Inc. since May 15, 2015. ... Dr. Miller was President and Chief Executive Officer of Red5 from 2013 to 2015.

Human genetics

Working as a Professor of Pathology at University of MIAMI Health system. finished PhD in 1985 from University of Rochester. My interests lie in understanding the relationship between the immune system and pathogens. More specifically, I am fascinated by the interactions between CD8+ T cells and the AIDS virus. This involves a comprehensive knowledge of the MHC class I molecules of humans and non-human primates. I have developed a program to understand this relationship over the past 20 years. More recently, I have devoted considerable time and effort to HIV vaccine development.

My interests lie in understanding the relationship between the immune system and pathogens. More specifically, I am fascinated by the interactions between CD8+ T cells and the AIDS virus. This involves a comprehensive knowledge of the MHC class I molecules of humans and non-human primates. I have developed a program to understand this relationship over the past 20 years. More recently, I have devoted considerable time and effort to HIV vaccine development.